VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Li Liu

Status: Unknown

Conditions: Brain Metastasis; Non Small Cell Lung Cancer

Treatments: Other: bevacizumab, standard chemotherapy and radiation

Study type: Observational

Funder types: Other

Identifiers

NCT01891708

XHZL02

Details and patient eligibility

About

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Full description

1. non small cell lung cancer (non squamous carcinoma)
2. ECOG 0-1
3. from 18-75 years old

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non squamous cell non small cell lung cancer
• with measurable disease
• ECOG 0-1

Exclusion criteria

• patients received surgery in recent 4 weeks